DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qrmhhj/modulators_of_the) has announced the addition of the "Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2015" report to their offering.
There are today 196 companies plus partners developing 282 targeting actin cytoskeleton modulator drugs in 1,242 developmental projects in cancer. In addition, there is 1 suspended drug, and the accumulated number of ceased drugs over the last years amounts to another 168 drugs. Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 164 different targets.
All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date, 162 out of the 164 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 34 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 27
- Pre-registration - 4
- Phase III - 38
- Phase II - 117
- Phase I - 145
- Preclinical - 132
- No Data - 4
- Suspended - 1
- Ceased - 168
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/qrmhhj/modulators_of_the.